#SARSCoV2#Omicron harbors a staggering 37 amino acid mutations in the spike with 15 of them in the receptor-binding domain (RBD), which is the main target of neutralizing antibodies. The number and positions of these mutations is concerning for tropism & immune evasion.
2/8
We found that the #SARSCoV2#Omicron RBD has ~2.5-fold enhanced ACE2 binding affinity, relative to the Wuhan-Hu-1 RBD, similar to what we previously showed for the Beta variant of concern.
We discovered that the #SARSCoV2#Omicron RBD, but not Alpha or Beta RBDs, bound mouse ACE2, likely due to Q493R which is similar to Q493K isolated upon mouse adaptation by @Baric_Lab
These data *putatively* reflect #Omicron expanded tropism
4/8
#SARSCoV2#Omicron immune evasion reduces plasma neutralizing activity up to 57x (convalescent) and up to 30-40x for Pfizer, Moderna or Astrazeneca vaccinees.
No neutralizing activity left with J&J (1x), Sputnik and Sinopharm for most subjects analyzed.
5/8
#SARSCoV2#Omicron mutations knock out 7 out of 8 monoclonal antibodies currently used in the clinic. Only S309, the parent of VIR-7832, retain neutralizing activity, with ~3x reduction relative to Wuhan-Hu-1.
A few other broadly neutralizing sarbecovirus antibodies are inhibiting #SARSCoV2#Omicron, including S2X259, S2H97 and S2K146. This is good news and shows that targeting conserved sarbecovirus RBD epitopes provides resilience to viral evolution!
In 2019, we proposed w @coronalexington @axiong_x that coronavirus entry into cells involves a spike (S) molecular ratcheting mechanism & discovered that antibodies could functionally mimic the receptor by inducing these S conformational changes
How many times did coronaviruses evolve the ability to use ACE2 as receptor for infection? Find out by reading this @biorxivpreprint in collab with Huan Yan (Wuhan Univ)
Led by Ma CB, Liu C @YoungjunPark11 Tang J & Chen J
We previously described the unexpected discovery that MERS-related coronaviruses (MERSr-CoVs) discovered in African bats use ACE2 as receptor instead of the MERS-CoV receptor DPP4 (as described in this thread )
It turns out that recently described MERSr-CoVs identified in European bats (MOW15-22 & PnNL2018B) with highly divergent receptor-binding motif (RBM) also use ACE2 but with a distinct and much narrower species tropism
A few months ago, we asked if imprinting impacts immune responses to the recently updated XBB.1.5 spike (S) #COVID19 booster? The peer-reviewed version of our manuscript is now available
@HHMINEWS @UWBiochemistry
During the review process, we added data showing elicitation of broadly neutralizing polyclonal plasma antibodies (Abs) against a wider ranger of #SARSCoV2 variants (now including HK.3 and JN.1) and at a later time point (~50 days post XBB.1.5 booster vaccination)
HKU1 was discovered in 2005 from a patient with pneumonia (it was circulating for ≥10 years) and is endemic in humans. HKU1 is an embecovirus, a subgenus for which the entry process into cells is less well understood than for most other betaCoVs such as #SARSCoV2
2/26
Recently, @Virus_Immunity @JBuchrieser @virusfusion007 and colleagues showed that human TMPRSS2 is an entry receptor for HKU1
Coronavirus spike (S) glycoproteins comprise the S1 subunit, which mediates attachment to host receptor(s), and the S2 subunit (fusion machinery) that promotes fusion of the viral and host membranes to initiate infection
2/22
The S2 subunit (fusion machinery) is much more conserved than the S1 subunit (comprising the RBD and NTD), and harbors several antigenic sites targeted by broadly neutralizing and protective monoclonal antibodies (Abs)
Immune imprinting - AKA original antigenic sin - describes how the first exposure to a virus shapes the immunological outcome of subsequent exposures to antigenically related strains.
2/18
Last year, we showed that Omicron infection of Wuhan-Hu-1 (Wu) mRNA vaccinees recalls cross-reactive memory B cells specific for epitopes shared by multiple #SARSCoV2 variants rather than priming naive B cells binding Omicron RBD-specific epitopes